NCT03358693 Molecular Signatures in Inflammatory Skin Disease
| NCT ID | NCT03358693 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Prof. Dr. Stephan Weidinger |
| Condition | Atopic Dermatitis |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2017-01-20 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2017-01-20 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This pilot project intends to examine the utility of a systems medicine approach to identify regulatory networks and their perturbation in psoriasis and atopic dermatitis, and to obtain a comprehensive perspective on disease and disease control by integrating and modelling data across multiple cellular levels and time following specific blockade of single pathophysiological factors through use of licensed biologics during routine care as systems biology challenge. To this end, ultra-deep phenotyping and prospective molecular characterization in short time-intervals and different disease equilibrium states will be carried out in targeted small sets of patients. The different layers and types of clinical and molecular information will then be integrated (integrative personal omics profiling iPOP) for generating insights into disease pathways and for extraction of molecular signatures that correspond to clinical severity scores. It will provide a good starting point for planning future trials aimed at identifying biological patterns useful for guiding targeted treatment.
Eligibility Criteria
Inclusion Criteria: * Ability to provide written informed consent and comply with the protocol * Dermatologist-diagnosed chronic inflammatory skin disease * Subject receives systemic therapy within routine care (in-label use of biologics) Exclusion Criteria: * Subject is unable to provide written informed consent or comply with the protocol. * Having used immunosuppressive/immunomodulating therapy or phototherapy within 4 weeks before the baseline visit. * Treatment of selected skin areas to be examined with topical corticosteroid or topical calcineurin inhibitor within 1 week before the baseline visit.
Contact & Investigator
Stephan Weidinger, MD
PRINCIPAL INVESTIGATOR
Department of Dermatology, university Hospital Schleswig-Holstein, Campus Kiel
Frequently Asked Questions
Who can join the NCT03358693 clinical trial?
This trial is open to participants of all sexes, studying Atopic Dermatitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03358693 currently recruiting?
Yes, NCT03358693 is actively recruiting participants. Contact the research team at sweidinger@dermatology.uni-kiel.de for enrollment information.
Where is the NCT03358693 trial being conducted?
This trial is being conducted at Kiel, Germany.
Who is sponsoring the NCT03358693 clinical trial?
NCT03358693 is sponsored by Prof. Dr. Stephan Weidinger. The principal investigator is Stephan Weidinger, MD at Department of Dermatology, university Hospital Schleswig-Holstein, Campus Kiel. The trial plans to enroll 300 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.